| 产品描述： | VU0134992 is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV |
| 靶点： |
IC50: 0.97 µM (Kir4.1) |
| 体内研究： |
VU0134992 (50-100 mg/kg; oral gavage) statistically significantly increased urinary Na+ as well as K+ excretion. Animal Model: Male Sprague-Dawley rats (250-300 g) Dosage: 50 and 100 mg/kg Administration: Oral gavage Result: Statistically significantly increased urinary Na+ as well as K+ excretion |
| 参考文献： |
1. Kharade SV, et al. Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992. Mol Pharmacol. 2018 Aug;94(2):926-937. |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.431 ml |
12.154 ml |
24.309 ml |
| 5 mM |
0.486 ml |
2.431 ml |
4.862 ml |
| 10 mM |
0.243 ml |
1.215 ml |
2.431 ml |
| 50 mM |
0.049 ml |
0.243 ml |
0.486 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京